Clinical Trials Logo

Advanced BRAF-mutant Cancers clinical trials

View clinical trials related to Advanced BRAF-mutant Cancers.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01616199 Terminated - Clinical trials for Advanced BRAF-mutant Cancers

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Start date: August 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the phase 1 portion of the study is to determine the maximally tolerated dose (MTD) or recommended dose (RD) and the safety/tolerability of PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. The purpose of the phase 2 portion of the study is to compare progression free survival (PFS), antitumor activity (response rate), disease control rate (DCR), and the safety and tolerability of PX-866 in combination with vemurafenib vs. vemurafenib alone in patients with advanced BRAF-mutant melanoma at the doses recommended from Phase 1.